{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132850","form_type":"8-K","ticker":null,"cik":"0001293971","company_name":"bluebird bio, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.856053+00:00","generated_at":"2026-05-20T02:28:44.061393+00:00","sec_items":["1.01","2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Carlyle and SK Capital complete acquisition of bluebird bio; stock delisted, new CEO David Meek","bullets":["Acquisition closed June 2, 2025; shareholders could elect $3.00 + one CVR per share, or $5.00 all-cash per share.","Approximately 59.8% of outstanding shares validly tendered before expiration; all conditions satisfied.","David Meek appointed CEO; prior CEO Andrew Obenshain and other executives terminated, eligible for severance.","Stock halted and delisted from Nasdaq; company will file Form 15 to terminate registration.","Carlyle and SK Capital provide primary capital to support scaled access to gene therapies for sickle cell, β-thalassemia, and CALD."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132850","json":"https://secwatch.observer/filing/0001193125-25-132850.json","markdown":"https://secwatch.observer/filing/0001193125-25-132850.md","text":"https://secwatch.observer/filing/0001193125-25-132850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/d39702d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:28:44.061393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"333b8315da","claim":"Najoh Tita-Reid departed as Director at bluebird bio, Inc..","evidence_excerpt":"each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a member"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"347029c1a4","claim":"Andrew Obenshain departed as Director at bluebird bio, Inc..","evidence_excerpt":"each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a member"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3d915fe0c1","claim":"Mark Vachon departed as Director at bluebird bio, Inc..","evidence_excerpt":"each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a member"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"43dec75dff","claim":"Richard Paulson departed as Director at bluebird bio, Inc..","evidence_excerpt":"each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a member"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"476d61885b","claim":"Joseph Vittiglio was terminated as other_named_officer at bluebird bio, Inc..","evidence_excerpt":"the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"}],"fact_type":"executive_change"},{"claim_id":"5fab15e7ee","claim":"Charlotte Jones-Burton departed as Director at bluebird bio, Inc..","evidence_excerpt":"each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a member"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5fc14bcaed","claim":"John O. Agwunobi departed as Director at bluebird bio, Inc..","evidence_excerpt":"each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a member"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"736780b77d","claim":"Nick Leschly departed as Director at bluebird bio, Inc..","evidence_excerpt":"each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a member"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bc58cc77bf","claim":"Andrew Obenshain was terminated as other_named_officer at bluebird bio, Inc..","evidence_excerpt":"the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"}],"fact_type":"executive_change"},{"claim_id":"e147197cd8","claim":"Mike Cloonan departed as Director at bluebird bio, Inc..","evidence_excerpt":"each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a member"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"eabf8eea83","claim":"Lis Leiderman departed as Director at bluebird bio, Inc..","evidence_excerpt":"each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a member"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f954a56b29","claim":"O. James Sterling was terminated as other_named_officer at bluebird bio, Inc..","evidence_excerpt":"the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"}],"fact_type":"executive_change"},{"claim_id":"bef889c5485a3d856ed322206a4225e81b5c41b3","claim":"bluebird bio, Inc.: Certificate of incorporation amended and restated in its entirety (effective 2025-06-02).","evidence_excerpt":"on June 2, 2025, the Company's certificate of incorporation and bylaws were each amended and restated in their entirety and, as so amended and restated, became the certificate of incorporation and bylaws of the Surviving Corporation.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-06-02"}],"fact_type":"governance_change"},{"claim_id":"e21554747a511ed2001ee622530c002d5f06e146","claim":"bluebird bio, Inc.: Bylaws amended and restated in their entirety (effective 2025-06-02).","evidence_excerpt":"on June 2, 2025, the Company's certificate of incorporation and bylaws were each amended and restated in their entirety and, as so amended and restated, became the certificate of incorporation and bylaws of the Surviving Corporation.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-06-02"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}